Lifeline for ALK cancer patients: continued access to targeted therapy

NCT ID NCT02584933

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 31 times

Summary

This study offers ongoing treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The goal is to keep providing the medicine and monitor its long-term safety. About 233 participants will take part, and they must have followed the rules of the earlier study and still be expected to benefit from continued treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Essex Oncology of North Jersey PA

Belleville, New Jersey, 07109, United States
Highlands Oncology Group

Fayetteville, Arkansas, 72703, United States
Loma Linda University

Loma Linda, California, 92354, United States
Maryland Oncology Hematology P A

Rockville, Maryland, 20850, United States
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Auckland, 1023, Australia
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Natal, Rio Grande do Norte, 59075 740, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Novartis Investigative Site

Barretos, São Paulo, 14784 400, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 01246 000, Brazil
Novartis Investigative Site

Sofia, 1303, Bulgaria
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Guangzhou, Guangdong, 510120, China
Novartis Investigative Site

Changchun, Jilin, 130012, China
Novartis Investigative Site

Beijing, 100039, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Montería, 230004, Colombia
Novartis Investigative Site

Brno, 656 53, Czechia
Novartis Investigative Site

Paris, 75231, France
Novartis Investigative Site

Paris, 75970, France
Novartis Investigative Site

Saint-Herblain, 44805, France
Novartis Investigative Site

Strasbourg, 67091, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Würzburg, 97074, Germany
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Meldola, FC, 47014, Italy
Novartis Investigative Site

Monza, MB, 20900, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Perugia, PG, 06129, Italy
Novartis Investigative Site

Aviano, PN, 33081, Italy
Novartis Investigative Site

Milan, 20141, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Novara, 28100, Italy
Novartis Investigative Site

Nagoya, Aichi-ken, 464 8681, Japan
Novartis Investigative Site

Fukuoka, Fukuoka, 811-1395, Japan
Novartis Investigative Site

Akashi, Hyōgo, 673-8558, Japan
Novartis Investigative Site

Koto Ku, Tokyo, 135-8550, Japan
Novartis Investigative Site

Beirut, 166830, Lebanon
Novartis Investigative Site

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site

Gdansk, 80-214, Poland
Novartis Investigative Site

Moscow, 115522, Russia
Novartis Investigative Site

Saint Petersburg, 192148, Russia
Novartis Investigative Site

Saint Petersburg, 197343, Russia
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

A Coruña, 15006, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Taichung, 40447, Taiwan
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 110, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taoyuan, 33305, Taiwan
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

ALK POSITIVE MALIGNANCIES ALK POSITIVE MALIGNANCIES